= C-X-C motif chemokine ligand 12; CXCR4 = C-X-C chemokine receptor type 4; CXCR7 = C-X-C chemokine receptor type 7; EGFR = epithelial growth factor receptor; ERK = extracellular signal-regulated kinase; GPCR = G-protein-coupled receptor; GRK = G protein-coupled receptor kinase; GSK-3β = glycogen synthase kinase-3β; Iκβα = nuclear factor κB inhibitor of nuclear factor κB; MEK = mitogenactivated protein kinase kinase; MI = myocardial infarction; mLST8 = mammalian lethal with SEC13 protein-8; mTOR = mechanistic target of rapamycin; NF-κB = nuclear factor-κB; p70s6k = 70 kDa ribosomal S6 kinase; PI3K = phosphoinositide 3-kinase; PKA = protein kinase A; PLC = phospholipase C; RAF = rapidly accelerated fibrosarcoma; Raptor = regulatory associated protein of mTOR; TGF = transforming growth factor; βAR = β-adrenergic receptor;
β-arr = β-arrestin; β-catenin = β-catenin.
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The authors have no financial conflicts of interest. Although the study has demonstrated the novel importance of β-arr2 in CPC survival, there are still numerous issues that need to be addressed before we can consider β-arr2 as a viable target to treat diseases. For example, while the current study showed the role of β-arr2 by using a knockout (KO) model, it is also important to investigate how overexpression (OE) of β-arr2 in CPCs can be useful for regenerative purposes. A previous work by McCrink et al. 8) using transgenic mouse hearts observed that cardiac β-arr2 OE increases cardiac function while reducing remodeling in post-MI. It will be very interesting to see the results of β-arr2 OE when employed in CPCs. In addition, we still have to uncover how β-arr2 fits into the whole timeline of HF. Future studies should consider investigating for the effect of β-arr1 and β-arr2 at different stages of HF progression. And even before we can ask this, we still have to have a better understanding of β-arr2 and the mechanisms related to it. What the authors failed to include in the current study is how β-arr2 KO affects βAR signaling in CPC survival, and how β-arr2 KO in CPCs directly interacts with known regulatory pathways by providing a direct evidence. Take for example, there were no clear links showing how protein kinase B (Akt), glycogen synthase kinase-3β (GSK-3β), and β-catenin is linked to β-arr2, and whether an alternative pathway via extracellular signal-regulated kinase (ERK) 1/2 can result in the same fate of cell survival. Furthermore, scientists are concerned regarding the effectivity of stem cell therapy. For instance, a clinical trial termed Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO) involving the use of CPCs showed encouraging results in the use of these cells in patients with HF, 9) but was later questioned by the journal, The Lancet, with Harvard University conducting its own investigations with regards to data integrity.
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The recent findings from the studies previously discussed demonstrate that the role β-arr is much more important than what we originally imagined. Targeting β-arr might not only be useful in HF-related diseases, but also in other metabolic diseases such as cancer, which was found to be related to tumor initiation time and cancer malignancy outcomes. 10) But as previously mentioned, there is still a lot to unravel. Researchers and clinicians should investigate how β-arr signal transduction can trigger a cascade of mechanisms that lead to the inhibition or progression of disease. Only after painting a clearer picture on its importance can we proceed with developing rational methods on how to harness β-arr for therapeutics. Nonetheless, the future of β-arr is bright and can be considered as a potential target for HF and metabolic disease management.
